Brokerages Expect The Clorox Company (NYSE:CLX) to Announce $0.98 EPS

Brokerages expect The Clorox Company (NYSE:CLXGet Rating) to announce earnings per share (EPS) of $0.98 for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Clorox’s earnings, with the lowest EPS estimate coming in at $0.95 and the highest estimate coming in at $1.07. Clorox reported earnings per share of $0.95 in the same quarter last year, which suggests a positive year over year growth rate of 3.2%. The business is expected to announce its next earnings report on Monday, January 1st.

On average, analysts expect that Clorox will report full-year earnings of $4.16 per share for the current fiscal year, with EPS estimates ranging from $4.12 to $4.25. For the next fiscal year, analysts expect that the firm will post earnings of $5.57 per share, with EPS estimates ranging from $4.98 to $6.10. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover Clorox.

Clorox (NYSE:CLXGet Rating) last issued its quarterly earnings data on Monday, May 2nd. The company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.97 by $0.34. Clorox had a return on equity of 92.98% and a net margin of 6.44%. The business had revenue of $1.81 billion during the quarter, compared to analysts’ expectations of $1.81 billion. During the same period in the previous year, the firm posted $1.62 earnings per share.

A number of equities analysts have recently issued reports on CLX shares. Atlantic Securities downgraded Clorox from a “neutral” rating to an “underweight” rating and set a $118.00 target price for the company. in a research note on Friday, February 4th. The Goldman Sachs Group lowered their target price on Clorox from $145.00 to $127.00 in a report on Tuesday, March 29th. Credit Suisse Group reduced their price target on Clorox from $160.00 to $155.00 and set an “underperform” rating on the stock in a research note on Friday, February 4th. Morgan Stanley lowered their target price on Clorox from $154.00 to $140.00 and set an “underweight” rating for the company in a research note on Friday, February 4th. Finally, StockNews.com started coverage on Clorox in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Ten research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Sell” and a consensus target price of $141.21.

In other Clorox news, COO Eric H. Reynolds sold 585 shares of Clorox stock in a transaction on Monday, May 9th. The shares were sold at an average price of $154.83, for a total value of $90,575.55. Following the completion of the sale, the chief operating officer now directly owns 17,289 shares of the company’s stock, valued at $2,676,855.87. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.58% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in shares of Clorox by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 14,685,046 shares of the company’s stock valued at $2,041,661,000 after purchasing an additional 185,012 shares during the last quarter. BlackRock Inc. raised its holdings in Clorox by 3.2% in the first quarter. BlackRock Inc. now owns 11,117,522 shares of the company’s stock worth $1,545,669,000 after buying an additional 342,680 shares during the last quarter. State Street Corp raised its holdings in Clorox by 4.1% in the fourth quarter. State Street Corp now owns 8,223,034 shares of the company’s stock worth $1,433,768,000 after buying an additional 327,488 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Clorox by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 2,331,231 shares of the company’s stock worth $405,639,000 after acquiring an additional 54,921 shares during the period. Finally, Morgan Stanley grew its position in Clorox by 12.2% during the third quarter. Morgan Stanley now owns 1,994,537 shares of the company’s stock valued at $330,317,000 after buying an additional 216,687 shares during the period. Hedge funds and other institutional investors own 77.28% of the company’s stock.

Clorox stock opened at $148.71 on Wednesday. The stock has a 50-day simple moving average of $145.71 and a 200-day simple moving average of $156.06. The company has a debt-to-equity ratio of 3.28, a quick ratio of 0.40 and a current ratio of 0.71. The company has a market capitalization of $18.30 billion, a P/E ratio of 40.30, a PEG ratio of 4.74 and a beta of 0.18. Clorox has a fifty-two week low of $127.02 and a fifty-two week high of $191.75.

About Clorox (Get Rating)

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brand names; professional cleaning and disinfecting products under the CloroxPro, Clorox Healthcare, and Clorox Total 360 brand names; professional food service products under the Hidden Valley brand name; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brand names in the United States.

Featured Articles

Get a free copy of the Zacks research report on Clorox (CLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.